about
Pharmacological brake-release of mRNA translation enhances cognitive memory2-Aminothiazoles as therapeutic leads for prion diseasesDrug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screeningStructure-based design of potent and ligand-efficient inhibitors of CTX-M class A β-lactamaseBroad-Spectrum Allosteric Inhibition of Herpesvirus ProteasesIdentification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model systemMining a cathepsin inhibitor library for new antiparasitic drug leadsPredicting binding to p-glycoprotein by flexible receptor dockingGenetic and neural mechanisms that inhibit Drosophila from mating with other species.A practical synthesis of differentially protected 2-(hydroxymethyl)piperazines.Discovery of 2-aminothiazoles as potent antiprion compounds.Hsp90 inhibitors as new leads to target parasitic diarrheal diseases.Simple one-pot synthesis of disulfide fragments for use in disulfide-exchange screening.Intramolecular [4 + 2] cycloadditions of iminoacetonitriles: a new class of azadienophiles for hetero Diels-Alder reactions.Successes and challenges in phenotype-based lead discovery for prion diseasesA high-throughput functional screen identifies small molecule regulators of temperature- and mechano-sensitive K2P channels.Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells.Modulating caspase activity: beyond the active site.Novel compounds lowering the cellular isoform of the human prion protein in cultured human cellsUCSF Small Molecule Discovery Center: innovation, collaboration and chemical biology in the Bay Area.Drug discovery for neglected tropical diseases at the Sandler Center.Investigating the antimalarial action of 1,2,4-trioxolanes with fluorescent chemical probesA fragmenting hybrid approach for targeted delivery of multiple therapeutic agents to the malaria parasiteIdentification and Optimization of Thienopyridine Carboxamides as Inhibitors of HIV Regulatory Complexes.Recent developments in the identification of novel oxazolidinone antibacterial agents.Chemical-biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target.Ferrous iron-dependent delivery of therapeutic agents to the malaria parasite.Drug discovery and development for neglected parasitic diseases.Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice.Hypothemycin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei [corrected].Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice.Drug resistance confounding prion therapeutics.Ferrous iron-dependent drug delivery enables controlled and selective release of therapeutic agents in vivoA Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion diseaseAntimalarial Drug Discovery: From Quinine to the Dream of Eradication.Antibacterial oxazolidinones: emerging structure-toxicity relationships.Fragment-based inhibitor discovery against β-lactamaseAllosteric Inhibitors, Crystallography, and Comparative Analysis Reveal Network of Coordinated Movement across Human Herpesvirus Proteases.Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major.
P50
Q21128794-70D372AF-87B5-49E0-8597-73F747E6ACCAQ24618566-68F573DE-561C-445B-A911-F246A337EED8Q27306843-FE682CCE-CE48-405B-9EDF-AA66728D5DBFQ27676983-A22C4CCA-3D7D-4321-86AF-E1F8AB80AD33Q27684483-CDB123CD-8589-4051-BAE1-CE6FFE83A119Q28477163-4644F9B3-C4D6-4209-A7D7-E9E3846223C0Q28478016-2D7D2709-87B1-41DC-BCC3-DC69A0EA9DE7Q28478693-CF39CEC6-1FA3-476C-8371-25FB1579ECFBQ30444806-15BFA5D2-22FD-48D7-8A0C-DBBCE0E1868CQ33301561-52CE99CD-50F6-4298-BCF6-1A2182B8AEA8Q33520644-8F860D4F-7963-40A1-848B-9244409CE50CQ33798454-51ACA428-3164-48FA-89D2-186648597992Q33875557-81ED4287-A3E0-4B08-9213-8AA4AAF7B2E0Q33944383-C8471A97-F515-40AB-B426-7BFFB7ED6129Q34104276-C5DD829F-3CCD-429A-82E3-EC192CE9D2FCQ34759487-F1AC4D03-0BD7-4160-B5DE-0A176E92070AQ35030768-A71684E2-FBFF-4534-A971-C4BEECFA2DDFQ35038530-890513EB-9989-4B1B-8964-4CA75B287183Q35094865-32BB4213-BD1E-4282-A522-EF52E537584AQ35128764-F84DBFFF-B1C5-4BC2-BCEA-BDAD07A660CAQ35419266-B2B804F5-1B16-4F5F-8938-DAA01E2F685AQ35610115-1BBFA2FE-EAB7-48F8-BDC6-32EB905D6AE7Q35694222-320935DE-FCCB-402F-9EB4-F04860369769Q36349096-600286CC-37E5-4287-9FCC-E252005283A8Q36417417-9F745465-0A3F-415E-B8D0-39D50FD76D1FQ36594213-5F5FDEDC-16B5-402B-88C6-BAFD9135A92BQ36616566-58565273-A2F9-4CE8-8670-ACDF4857D2DFQ36654913-299456D3-919D-42A6-9280-D7654F90CDE2Q36806526-3B7A3AB2-E047-4F42-851C-ADCDC4BF3029Q36998826-0C2EFB87-A943-4D5B-9F9F-F07C86FEC7CFQ37252008-517036A7-C99F-4F74-8E0B-C9FEC54D728CQ37276740-AB1C510E-8B00-4F12-B06D-CB076165A5E3Q37318264-CF759911-86E2-43E6-8EA7-CF1AB7B8C5C9Q37532072-7A06EC2A-0EA0-4A48-B13E-9038949B8B9CQ37698596-4161F4F0-72E0-486F-827D-8D29BBF1457FQ37727791-653E4926-6E09-403C-A0FF-5E03328FBD49Q37747401-A753F379-C6A3-4E87-A76F-7CB38EF7B921Q38196443-3B5E516C-33B7-4E3A-A460-28023EE483ECQ38651856-044A9392-93CD-4E76-BD80-B572F3861E8FQ39348237-36B182E8-B277-4FA5-AB07-CBC3163BC6EA
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Adam R Renslo
@en
Adam R Renslo
@es
Adam R Renslo
@nl
Adam R Renslo
@sl
Adam Renslo
@fr
type
label
Adam R Renslo
@en
Adam R Renslo
@es
Adam R Renslo
@nl
Adam R Renslo
@sl
Adam Renslo
@fr
prefLabel
Adam R Renslo
@en
Adam R Renslo
@es
Adam R Renslo
@nl
Adam R Renslo
@sl
Adam Renslo
@fr
P108
P106
P21
P31
P496
0000-0002-1240-2846